Scott Williams

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin M Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, et al.

Journal article  |  2021  |  Eur Urol

Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than me..

Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses.

Joseph Sia, Jim Hagekyriakou, Ioana Chindris, Hassan Albarakati, Trevor Leong, Ramona Schlenker, Simon P Keam, Scott G Williams, Paul J Neeson, Ricky W Johnstone, Nicole M Haynes

Journal article  |  2021  |  Int J Radiat Oncol Biol Phys

PURPOSE: We examined how radiation dose per fraction (DPF) and total dose, as represented by biological effective dose (BED), can ..

UpFrontPSMA: a randomized phase 2 study of sequential Lu-177-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)

Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, David A Pattison, Roslyn J Francis, Scott Williams, Shahneen Sandhu, Ian D Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G Murphy, Michael S Hofman, Arun A Azad

Journal article  |  2021  |  BJU INTERNATIONAL

OBJECTIVE: To assess the activity and safety of sequential lutetium-177 (177 Lu)-PSMA-617 and docetaxel vs docetaxel on a backgrou..

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.

Rafael E de Feria Cardet, Michael S Hofman, Tatiana Segard, Jackie Yim, Scott Williams, Roslyn J Francis, Mark Frydenberg, Nathan Lawrentschuk, Declan G Murphy, Richard De Abreu Lourenco

Journal article  |  2021  |  Eur Urol

BACKGROUND: Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)..

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of Lu-177-PSMA-617 Prior to Prostatectomy

Nattakorn Dhiantravan, John Violet, Renu Eapen, Omar Alghazo, Mark Scalzo, Price Jackson, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Sandhu, Scott G Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Journal article  |  2021  |  EUROPEAN UROLOGY FOCUS

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium..

[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Andrew Weickhardt, Andrew M Scott, Sze-Ting Lee, Edmond M Kwan, Arun A Azad, Shakher Ramdave, Andrew D Redfern, et al.

Journal article  |  2021  |  LANCET

BACKGROUND: Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prosta..

Standard versus hypofractionated intensity-modulated radiotherapy for prostate cancer: assessing the impact on dose modulation and normal tissue effects when using patient-specific cancer biology

EJ Her, MA Ebert, A Kennedy, HM Reynolds, Y Sun, S Williams, A Haworth

Journal article  |  2021  |  PHYSICS IN MEDICINE AND BIOLOGY

Hypofractionation of prostate cancer radiotherapy achieves tumour control at lower total radiation doses, however, increased recta..

Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study).

Omar Alghazo, Renu Eapen, Nattakorn Dhiantravan, John A Violet, Price Jackson, Mark Scalzo, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Kaur Sandhu, Scott Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

TPS264 Background: High-risk localised prostate cancer (HRCaP) is treated by radical prostatectomy (RP) or radiotherapy. Despite ..

177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).

Michael S Hofman, Louise Emmett, Shahneen Kaur Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Alison Yan Zhang, Margaret Mary McJannett, Martin R Stockler, John A Violet, Scott Williams, Andrew James Martin, Ian D Davis

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

6 Background: TheraP is a randomized phase 2 trial that showed LuPSMA significantly improved the primary endpoint of PSA≥50% redu..

UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).

Arun Azad, Nattakorn Dhiantravan, Louise Emmett, Anthony M Joshua, Ian Vela, David A Pattison, Roslyn J Francis, Scott Williams, Shahneen Kaur Sandhu, Ian D Davis, Nitika Neha, Mathias Bressel, Declan G Murphy, Michael S Hofman

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

TPS180 Background: 177Lu‐PSMA-617 (Lu-PSMA) is a radiolabeled small-molecule that binds with high affinity to PSMA enabling highl..